Clinical Trial Update: Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

View source ↗

Summary

Enrollment by invitation continues for a long-term follow-up study of an investigational gene therapy targeting PKP2-related arrhythmogenic cardiomyopathy (Lexe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmogenic Cardiomyopathy
• Arrhythmogenic Right Ventricular Cardiomyopathy

Drugs mentioned

• Lexeo Therapeutics investigational gene therapy for PKP2-related arrhythmogenic cardiomyopathy

Snippet

Sponsor: Lexeo Therapeutics | Conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM | Status: ENROLLING_BY_INVITATION